Recently, many have shown that targeting BCL-xL and MCL-1 in combination, is highly efficacious in variety of solid disease settings such as cervical cancer, MPM, melanoma and non-small cell lung cancer26,27,36–38. This evidence concerns the gene BCL2L1 and melanoma.